サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1742555

RSウイルスワクチン市場：世界の産業分析、規模、シェア、成長、動向、2025～2035年予測

Respiratory Syncytial Virus Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
RSウイルスワクチン市場：世界の産業分析、規模、シェア、成長、動向、2025～2035年予測
出版日: 2025年04月23日
発行: Transparency Market Research
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

RSウイルスワクチン市場- 調査範囲

TMRの調査レポート「RSウイルスワクチンの世界市場」は、2025～2035年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2025年を基準年、2035年を予測年として、2019～2035年までの世界のRSウイルスワクチン市場の収益と予測を提供します。また、2025～2035年までの世界のRSウイルスワクチン市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、RSウイルスワクチン市場を推察しました。

市場スナップショット
2024年の市場規模 37億米ドル
2035年の市場規模 159億米ドル
CAGR 13.8%

当レポートでは、世界のRSウイルスワクチン市場の競合情勢について調査しています。世界のRSウイルスワクチン市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界のRSウイルスワクチン市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界のRSウイルスワクチン市場分析と予測、2020～2035年

第5章 主要洞察

  • 主要国のヘルスケア費支出データ
  • 技術的進歩
  • 主要地域/国における規制シナリオ
  • ポーターのファイブフォース分析
  • PESTEL分析
  • 主要な業界イベント

第6章 世界の市場分析と予測：ワクチンの種類別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：ワクチンの種類別、2020～2035年
    • 組み換え/サブユニットワクチン
    • mAB注射
    • mRVワクチン
    • その他
  • 市場の魅力：ワクチンの種類別

第7章 世界の市場分析と予測：年齢層別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：年齢層別、2020～2035年
    • 成人および老年医学
    • 子供および妊婦
  • 市場の魅力：年齢層別

第8章 世界の市場分析と予測：販売チャネル別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：販売チャネル別、2020～2035年
    • 小売薬局
    • 病院薬局
    • その他
  • 市場の魅力：販売チャネル別

第9章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第10章 北米の市場分析と予測

  • 米国
  • カナダ

第11章 欧州の市場分析と予測

  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域

第12章 アジア太平洋地域の市場分析と予測

  • 中国
  • 日本
  • インド
  • オーストラリアとニュージーランド
  • その他アジア太平洋地域

第13章 ラテンアメリカ地域の市場分析と予測

  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域

第14章 中東・アフリカの市場分析と予測

  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第15章 競合情勢

  • 市場企業-競合マトリックス（企業階層別・規模別）
  • 市場シェア分析企業別（2024年）
  • 企業プロファイル
    • GSK plc
    • Moderna, Inc.
    • Pfizer, Inc.
    • Sanofi
    • AstraZeneca
    • MAXVAX Biotechnology Limited
    • Guangzhou Patronus Biotech Co., Ltd.
    • Sinocelltech Ltd.
    • Shenzhen Shenxin Biotechnology Co., Ltd
    • Starna Therapeutics
    • Blue Lake Biotechnology Inc.
図表

List of Tables

  • Table 01: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Vaccine Type, 2020-2035
  • Table 02: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 03: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 04: Global Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Region, 2020-2035
  • Table 05: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 06: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 07: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 08: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 09: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 10: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 11: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 12: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 13: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 14: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 15: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 16: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 17: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 18: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 19: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 20: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035
  • Table 21: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2035
  • Table 22: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2020-2035
  • Table 23: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Age Group, 2020-2035
  • Table 24: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, By Sales Channel, 2020-2035

List of Figures

  • Figure 01: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 02: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 03: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Recombinant / Subunit Vaccines, 2020-2035
  • Figure 04: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by mAB Injection, 2020-2035
  • Figure 05: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by mRNA Vaccines, 2020-2035
  • Figure 06: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Others, 2020-2035
  • Figure 07: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 08: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 09: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Adults & Geriatrics, 2020-2035
  • Figure 10: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Children & Pregnant Mothers, 2020-2035
  • Figure 11: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 12: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 13: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Retail Pharmacies, 2020-2035
  • Figure 14: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Hospital Pharmacies, 2020-2035
  • Figure 15: Global Respiratory Syncytial Virus Vaccine Market Revenue (US$ Mn), by Others, 2020-2035
  • Figure 16: Global Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 17: Global Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Region, 2025-2035
  • Figure 18: North America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 19: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 20: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 21: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 22: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 23: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 24: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 25: North America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 26: North America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 27: Europe Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 28: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 29: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 30: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 31: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 32: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 33: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 34: Europe Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 35: Europe Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 36: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 37: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 38: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 39: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 40: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 41: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 42: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 43: Asia Pacific Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 44: Asia Pacific Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 45: Latin America Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 46: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 47: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 48: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 49: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 50: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 51: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 52: Latin America Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 53: Latin America Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
  • Figure 54: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 55: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 56: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 57: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Vaccine Type, 2024 and 2035
  • Figure 58: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Vaccine Type, 2025-2035
  • Figure 59: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Age Group, 2024 and 2035
  • Figure 60: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Age Group, 2025-2035
  • Figure 61: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Value Share Analysis, By Sales Channel, 2024 and 2035
  • Figure 62: Middle East and Africa Respiratory Syncytial Virus Vaccine Market Attractiveness Analysis, By Sales Channel, 2025-2035
目次
Product Code: TMRGL86639

Respiratory Syncytial Virus Vaccine Market - Scope of Report

TMR's report on the global respiratory syncytial virus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global respiratory syncytial virus vaccine market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global respiratory syncytial virus vaccine market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the respiratory syncytial virus vaccine market.

Market Snapshot
Market Value in 2024US$ 3.7 Bn
Market Value in 2035US$ 15.9 Bn
CAGR13.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global respiratory syncytial virus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global respiratory syncytial virus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory syncytial virus vaccine market.

The report delves into the competitive landscape of the global respiratory syncytial virus vaccine market. Key players operating in the global respiratory syncytial virus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory syncytial virus vaccine market profiled in this report.

Key Questions Answered in global respiratory syncytial virus vaccine Market Report:

  • What is the sales/revenue generated by respiratory syncytial virus vaccine across all regions during the forecast period?
  • What are the opportunities in the global respiratory syncytial virus vaccine market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Respiratory Syncytial Virus Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global respiratory syncytial virus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory syncytial virus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory syncytial virus vaccine market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Respiratory Syncytial Virus Vaccine Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Healthcare Expenditure Data Across Key Countries
  • 5.2. Technological Advancements
  • 5.3. Regulatory Scenario across Key Regions / Countries
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. PESTEL Analysis
  • 5.6. Key Industry Events

6. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Vaccine Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Vaccine Type, 2020-2035
    • 6.3.1. Recombinant/Subunit Vaccines
    • 6.3.2. mAB Injection
    • 6.3.3. mRVaccines
    • 6.3.4. Others
  • 6.4. Market Attractiveness By Vaccine Type

7. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Age Group

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Age Group, 2020-2035
    • 7.3.1. Adults & Geriatrics
    • 7.3.2. Children & Pregnant Mothers
  • 7.4. Market Attractiveness By Age Group

8. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Sales Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Sales Channel, 2020-2035
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Sales Channel

9. Global Respiratory Syncytial Virus Vaccine Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Region

10. North America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 10.2.1. Recombinant/Subunit Vaccines
    • 10.2.2. mAB Injection
    • 10.2.3. mRVaccines
    • 10.2.4. Others
  • 10.3. Market Value Forecast By Age Group, 2020-2035
    • 10.3.1. Adults & Geriatrics
    • 10.3.2. Children & Pregnant Mothers
  • 10.4. Market Value Forecast By Sales Channel, 2020-2035
    • 10.4.1. Retail Pharmacies
    • 10.4.2. Hospital Pharmacies
    • 10.4.3. Others
  • 10.5. Market Value Forecast By Country, 2020-2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Vaccine Type
    • 10.6.2. By Age Group
    • 10.6.3. By Sales Channel
    • 10.6.4. By Country

11. Europe Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 11.2.1. Recombinant/Subunit Vaccines
    • 11.2.2. mAB Injection
    • 11.2.3. mRVaccines
    • 11.2.4. Others
  • 11.3. Market Value Forecast By Age Group, 2020-2035
    • 11.3.1. Adults & Geriatrics
    • 11.3.2. Children & Pregnant Mothers
  • 11.4. Market Value Forecast By Sales Channel, 2020-2035
    • 11.4.1. Retail Pharmacies
    • 11.4.2. Hospital Pharmacies
    • 11.4.3. Others
  • 11.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Vaccine Type
    • 11.6.2. By Age Group
    • 11.6.3. By Sales Channel
    • 11.6.4. By Country / Sub-region

12. Asia Pacific Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 12.2.1. Recombinant/Subunit Vaccines
    • 12.2.2. mAB Injection
    • 12.2.3. mRVaccines
    • 12.2.4. Others
  • 12.3. Market Value Forecast By Age Group, 2020-2035
    • 12.3.1. Adults & Geriatrics
    • 12.3.2. Children & Pregnant Mothers
  • 12.4. Market Value Forecast By Sales Channel, 2020-2035
    • 12.4.1. Retail Pharmacies
    • 12.4.2. Hospital Pharmacies
    • 12.4.3. Others
  • 12.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Vaccine Type
    • 12.6.2. By Age Group
    • 12.6.3. By Sales Channel
    • 12.6.4. By Country / Sub-region

13. Latin America Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 13.2.1. Recombinant/Subunit Vaccines
    • 13.2.2. mAB Injection
    • 13.2.3. mRVaccines
    • 13.2.4. Others
  • 13.3. Market Value Forecast By Age Group, 2020-2035
    • 13.3.1. Adults & Geriatrics
    • 13.3.2. Children & Pregnant Mothers
  • 13.4. Market Value Forecast By Sales Channel, 2020-2035
    • 13.4.1. Retail Pharmacies
    • 13.4.2. Hospital Pharmacies
    • 13.4.3. Others
  • 13.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Vaccine Type
    • 13.6.2. By Age Group
    • 13.6.3. By Sales Channel
    • 13.6.4. By Country / Sub-region

14. Middle East & Africa Respiratory Syncytial Virus Vaccine Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Vaccine Type, 2020-2035
    • 14.2.1. Recombinant/Subunit Vaccines
    • 14.2.2. mAB Injection
    • 14.2.3. mRVaccines
    • 14.2.4. Others
  • 14.3. Market Value Forecast By Age Group, 2020-2035
    • 14.3.1. Adults & Geriatrics
    • 14.3.2. Children & Pregnant Mothers
  • 14.4. Market Value Forecast By Sales Channel, 2020-2035
    • 14.4.1. Retail Pharmacies
    • 14.4.2. Hospital Pharmacies
    • 14.4.3. Others
  • 14.5. Market Value Forecast By Country / Sub-region, 2020-2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Vaccine Type
    • 14.6.2. By Age Group
    • 14.6.3. By Sales Channel
    • 14.6.4. By Country / Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. GSK plc
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Moderna, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Pfizer, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Sanofi
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. AstraZeneca
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. MAXVAX Biotechnology Limited
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Guangzhou Patronus Biotech Co., Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Sinocelltech Ltd.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Shenzhen Shenxin Biotechnology Co., Ltd
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Starna Therapeutics
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments
    • 15.3.11. Blue Lake Biotechnology Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments